Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SHBG | P04278 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TST | Q16762 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10983126 | 0.98 | ESR1 (0.53) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| SCHEMBL9440297 | 0.98 | ESR1 (0.53) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| SCHEMBL8028115 | 0.98 | ESR1 (0.53) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| SCHEMBL6622409 | 0.93 | CA2 (0.47) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| SCHEMBL30518612 | 0.84 | CA2 (0.43) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| SCHEMBL6181011 | 0.84 | CA2 (0.43) | CYP3A4ALDH1A1LMNACA2LPL | |
| SCHEMBL5222347 | 0.80 | HTR2A (0.57) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| SCHEMBL5305758 | 0.78 | HTR2A (0.61) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| SCHEMBL10645352 | 0.78 | HTR2A (0.61) | CYP3A4ESR1ADRA2AADORA3TACR2 | |
| Bromide SCHEMBL11492916 | 0.78 | ESR1 (0.55) | CYP3A4ESR1ADRA2AADORA3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084171-B1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | SHOWA DENKO KK (JP) | 2013-04-10 | — | — | EP | disclosed |
| CN-101535325-B | Iridium complex compound, organic electroluminescent device obtained using the same, and use of the device | SHOWA DENKO KK | 2012-07-04 | — | — | CN | disclosed |
| US-20090315454-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | SHOWA DENKO K.K. (JP) | 2009-12-24 | — | — | US | disclosed |
| CN-101535325-A | Iridium complex compound, organic electroluminescent device obtained using the same, and use of the device | SHOWA DENKO KK (JP) | 2009-09-16 | — | — | CN | disclosed |
| EP-2084171-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | Showa Denko K.K. (JP) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008056799-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | SHOWA DENKO K.K. (JP) | 2008-05-15 | — | — | WO | disclosed |
| CN-1315859-C | Lincomycin derivatives possessing antibacterial activity | VICURON PHARM INC (US) | 2007-05-16 | — | — | CN | disclosed |
| US-7199105-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7164011-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1654268-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| CN-1681832-A | Lincomycin derivatives possessing antibacterial activity | VICURON PHARM INC (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1529052-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040116690-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004016632-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | CYP3A4 3577/4885ESR1 4176/4885ADRA2A 4529/4885 |
| US-20090315454-A1 | IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE | ELP1, RUVBL1, LIG1 | CYP3A4 2449/4885ESR1 121/4885ADRA2A 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.